Back to News
Market Impact: 0.32
AnaptysBio Swings To Profit In Q2 Reflecting $181.5 Mln Tax Benefit
Source: Nasdaq
Healthcare & BiotechCorporate EarningsM&A & RestructuringCompany Fundamentals
AnaptysBio reported a Q2 2026 profit, primarily driven by a significant tax benefit following its separation from First Tracks Biotherapeutics. Collaboration revenue also increased, supported by higher activity, although the available article text does not provide specific financial figures or guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.28
Ticker Sentiment
ANAB0.58
More News
- Further turmoil could be in store for tech stocks. What to watch in the week ahead
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- The AI ‘credit card’ is getting costlier as CoreWeave bond yield tops 16%
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says